2024 · FINDING
TAZPOWER Phase 3
Elamipretide improved knee extensor strength and 6MWD in Barth syndrome. FDA PDUFA date Q4 2025.
⚠ RESEARCH USE ONLY · NOT FDA-APPROVED FOR HUMAN USE · NOT MEDICAL ADVICE
LONGEVITYPHASE 3 TRIALS
SS-31.
Mitochondria-targeting peptide with the most rigorous longevity data
AKA · Elamipretide · MTP-131 · Bendavia
LONGEVITYSUBCUTANEOUS
A cell-penetrating tetrapeptide designed specifically to concentrate in the inner mitochondrial membrane. Phase 3 trials in Barth syndrome and primary mitochondrial myopathy; off-label interest for exercise capacity and cellular aging.
~4 hours plasma; tissue accumulation
Half-life
3
Citations
1
Routes
1
Categories
71
Popularity
AT A GLANCE.
§ 01 · TL;DRTHE QUICK READ.
A cell-penetrating tetrapeptide designed specifically to concentrate in the inner mitochondrial membrane. Phase 3 trials in Barth syndrome and primary mitochondrial myopathy; off-label interest for exercise capacity and cellular aging.
Targets the inner mitochondrial membrane. Binds to cardiolipin, protects it from oxidation, and restores mitochondrial efficiency in aged or damaged cells.
Research doses in healthy adults much lower (5–10mg).
WHAT IT MIGHT HELP WITH.
1
Improves mitochondrial ATP production
2
Reduces oxidative stress and ROS generation
3
Phase 3 investigational for Barth syndrome (rare mito disease)
4
Improves 6-minute walk distance in mitochondrial myopathy
5
Preliminary data on cardiac ischemia-reperfusion protection
HOW IT WORKS.
§ 02 · MECHANISMTargets the inner mitochondrial membrane. Binds to cardiolipin, protects it from oxidation, and restores mitochondrial efficiency in aged or damaged cells.
Aromatic-cationic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that selectively binds cardiolipin. Prevents cardiolipin peroxidation, stabilizes electron transport chain supercomplexes, reduces ROS leak, restores ATP production in dysfunctional mitochondria.
WHO IT'S FOR
- ✓Mitochondrial disease research
- ✓Longevity/healthspan researchers
WHO SHOULD AVOID
- ✕Pregnancy
- ✕Acute infection
THE RESEARCH.
§ 03 · 3 STUDIES2013 · FINDING
Siegel et al. — aged muscle
Single dose restored mitochondrial function in muscle of aged mice to young levels.
2018 · FINDING
Szeto — cardiolipin review
Comprehensive review: SS-31 uniquely targets cardiolipin without generic antioxidant effects.
DOSING PROTOCOL.
§ 04 · DOSINGTYPICAL RANGE
Research doses in healthy adults much lower (5–10mg).
40mg subcutaneous daily (TAZPOWER Ph III protocol)
FREQUENCY
Most-cited schedule
Once daily
ROUTES
Delivery methods
SUBCUTANEOUS
HALF-LIFE
Steady state drives frequency
~4 hours plasma; tissue accumulation
⚠ NOTE
These are reported protocols from research literature and practitioner accounts, not prescriptions. No FDA-approved human dose exists for research compounds. Anyone using SS-31 should work with a qualified physician and source from a supplier providing third-party COAs.
FORMS AVAILABLE
- · Solution vial
⚠ RESEARCH INFORMATION ONLY · NOT MEDICAL ADVICE
SIDE EFFECTS & RISKS.
§ 06 · SAFETY·
Injection site reactions
Common · mild
·
Headache
Occasional · mild
·
Dizziness
Occasional · mild
WHERE TO SOURCE
§ 07 · SUPPLIERPEAK LAB
PEPTIDES
PEPTIDES
SUPPLIER OF RECORD · 12 BATCHES PASSED
We tried nine suppliers across 2025 and kept picking PEAK LAB for SS-31: 99.4% HPLC purity, COA on every batch, cold chain intact. Shop through our link and we earn a small commission — affiliate relationship is disclosed.
◆ THE PEPGAINS DISPATCH
GET THE NEXT UPDATE FIRST.
New research on SS-31 + a weekly dispatch on everything else moving in the peptide world. One email. Unsubscribe in a click.